Antibodies against MAEBL ligand domains M1 and M2 inhibit sporozoite development in vitro.
MAEBL is a type 1 membrane protein that is implicated in the merozoite invasion of erythrocytes and sporozoite invasion of mosquito salivary glands. This apical organelle protein is structurally similar to the ebl erythrocyte binding proteins, such as EBA-175, except that the tandem ligand domains of MAEBL are similar to part of the extracellular domain of apical membrane antigen 1 and not the Duffy binding-like domain. Although midgut and salivary gland sporozoites are morphologically similar, salivary gland sporozoites undergo a period of new gene expression after infecting the salivary glands, display distinct phenotypic differences, and are more infectious for the mammalian host. The objectives of this project were to determine the molecular form of MAEBL in the infectious salivary gland sporozoites and whether the ligand has a role in the sporozoite development to exoerythrocytic stages in hepatocytes. We determined that MAEBL is newly expressed in salivary gland sporozoites and in a form distinct from what is present in the midgut sporozoites or present in erythrocytic stages. Both ligand domains (M1 and M2) were expressed as part of a full-length membrane form of MAEBL in the salivary gland sporozoites in contrast to the other stages that retain only the M2 ligand domain as part of the membrane form of the protein. Antisera developed against the cysteine-rich regions of the extracellular portion of MAEBL inhibited sporozoite development to exoerythrocytic forms in vitro. Together these data indicate that MAEBL has a role in this third developmental stage in the life cycle of the malaria parasite. Thus, MAEBL is another target for pre-erythrocytic-stage vaccine development against malaria parasites.
Preiser
Peter
P
Division of Parasitology, National Institute for Medical Research, London, United Kingdom.
Rénia
Laurent
L
Singh
Naresh
N
Balu
Bharath
B
Jarra
William
W
Voza
Tatiana
T
Kaneko
Osamu
O
Blair
Peter
P
Torii
Motomi
M
Landau
Irène
I
Adams
John H
JH
D000818:Animals; D000852:Anopheles / Q000469:parasitology; D000913:Antibodies, Protozoan / Q000276:immunology* / Q000494:pharmacology; D002352:Carrier Proteins / Q000737:chemistry / Q000276:immunology*; D022781:Hepatocytes / Q000469:parasitology; D006801:Humans; D010963:Plasmodium falciparum / Q000254:growth & development* / Q000276:immunology; D010967:Plasmodium yoelii / Q000254:growth & development* / Q000276:immunology; D015800:Protozoan Proteins / Q000737:chemistry / Q000276:immunology*; D011956:Receptors, Cell Surface; D012469:Salivary Glands / Q000378:metabolism / Q000469:parasitology; D034101:Sporozoites / Q000187:drug effects / Q000254:growth & development*
D000913:Antibodies, Protozoan; D002352:Carrier Proteins; C468522:MAEBL protein, Plasmodium falciparum; D015800:Protozoan Proteins; D011956:Receptors, Cell Surface